Breakthrough in Cancer Fight?
- MAGDEBURG, Germany – Chemists at the Otto von guericke University Magdeburg have achieved a significant breakthrough in cancer research, successfully synthesizing Disorazole Z1, a potent anti-cancer compound, in...
- Disorazole Z1, known for its cytotoxicity, effectively prevents cell division and destroys cells.
- Dieter Schinzer,from the Institute of Chemistry,emphasized the compound's potency.
synthetic production of Disorazole Z1 Offers New Hope for Cancer Treatment
MAGDEBURG, Germany – Chemists at the Otto von guericke University Magdeburg have achieved a significant breakthrough in cancer research, successfully synthesizing Disorazole Z1, a potent anti-cancer compound, in the laboratory for the first time.
Disorazole Z1: A Powerful Natural Compound
Disorazole Z1, known for its cytotoxicity, effectively prevents cell division and destroys cells. The compound, originally derived from myxobacteria found in decaying organic matter, has been the subject of scientific studies exploring its potential in cancer therapies.
Dieter Schinzer,from the Institute of Chemistry,emphasized the compound’s potency. “The substance is extremely active, even at picomolar concentrations,” Schinzer said. He noted the precautions taken during the initial synthesis, including the use of protective gear, to ensure safety.
synthetic Production: A Leap Forward
The ability to synthesize disorazole Z1 is a major advancement, as the compound was previously only obtainable from bacteria. This synthetic production allows for modifications to optimize its properties for medical use.
“we have imitated nature, but with a decisive advantage,” Schinzer stated. “Unlike bacteria, which produce Disorazole Z1 in a fixed form, we can adapt it specifically and optimize it for medical applications.”
Targeted Cancer Treatment
The next step involves modifying the molecule to target specific proteins or antibodies, guiding it directly to tumors. This would allow the active ingredient to inhibit tumor cell division while minimizing harm to healthy cells.
Schinzer explained that the goal is to ensure cell death, or apoptosis, occurs only where intended. The university is collaborating with industry partners to refine the substance, aiming for a treatment that selectively attacks cancer cells.
Patenting and Future Research
The university plans to quickly patent and publish the findings. Further research will focus on the compound’s medical applicability and optimizing its synthesis for industrial production.
“We have developed innovative strategies to build the molecule in several steps,” Schinzer said. “the most modern chemical techniques and analytical methods were used to confirm the exact structure of the synthesized connection.”